glucagon has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (1,3-dipropyl-8-cyclopentylxanthine) | Trials (1,3-dipropyl-8-cyclopentylxanthine) | Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 1,301 | 1 | 165 |
| Protein | Taxonomy | glucagon (IC50) | 1,3-dipropyl-8-cyclopentylxanthine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0051 | |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | 0.0038 | |
| Adenosine receptor A2a | Homo sapiens (human) | 0.2033 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.0234 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández, J; Juan-Fita, MJ; Vargas, ML | 1 |
1 other study(ies) available for glucagon and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adrenergic beta-Antagonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Female; Glucagon; Heart Ventricles; Imidazoles; In Vitro Techniques; Male; Myocardial Contraction; Phosphodiesterase I; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Quinolones; Rats; Rats, Sprague-Dawley; Ventricular Function; Xanthines | 2005 |